Last updated: August 22, 2026
Trulicity, Eli Lilly’s once-weekly dulaglutide injection, remains a major diabetes franchise but is in structural decline. Reported sales rose from approximately $6.5 billion in 2021 to $7.4 billion in 2022 before falling to about $6.0 billion in 2023 and roughly $5.0 billion in 2024. The decline reflects direct substitution by Lilly’s Mounjaro and Zepbound, Novo Nordisk’s Ozempic and Wegovy, supply normalization across the GLP-1 class, and the absence of an obesity indication for Trulicity.[1][2]
Trulicity still generates substantial cash flow and has a large installed patient base. Its commercial value is shifting from growth asset to mature cash-generating product. The principal medium-term risk is accelerated erosion from newer incretin medicines, while the principal legal risk is follow-on competition after the core U.S. patent position expires.
What is Trulicity and how does dulaglutide compete?
Trulicity contains dulaglutide, a recombinant GLP-1 receptor agonist administered once weekly through a single-dose pen. The FDA approved Trulicity in September 2014 for adults with Type 2 diabetes as an adjunct to diet and exercise.[3]
Its principal commercial attributes are:
| Attribute |
Trulicity |
| Active ingredient |
Dulaglutide |
| Manufacturer |
Eli Lilly |
| FDA approval |
September 2014 |
| Primary indication |
Type 2 diabetes |
| Administration |
Once weekly, subcutaneous |
| Available strengths |
0.75 mg, 1.5 mg, 3 mg, and 4.5 mg |
| Obesity indication |
None |
| Product type |
Recombinant biologic |
| Main competitors |
Mounjaro, Ozempic, Rybelsus, Victoza, Wegovy |
| U.S. regulatory pathway |
Biologics license application, or BLA |
Trulicity’s once-weekly dosing and pen-based delivery supported rapid adoption. The product also benefited from cardiovascular-risk-reduction data in the REWIND trial, which reported a significant reduction in major adverse cardiovascular events in a broad Type 2 diabetes population.[4]
The commercial limitation is that dulaglutide does not match the weight-loss profile or market positioning of tirzepatide and semaglutide. Trulicity is primarily a diabetes product, while Mounjaro, Ozempic, Wegovy, and Zepbound have expanded the incretin market into obesity treatment and chronic weight management.
How have Trulicity sales changed?
Trulicity sales peaked in 2022. Eli Lilly’s reported product revenue trajectory was approximately:
| Year |
Trulicity revenue |
Approximate year-over-year change |
| 2021 |
$6.5 billion |
Growth |
| 2022 |
$7.4 billion |
About 15% increase |
| 2023 |
$6.0 billion |
About 19% decline |
| 2024 |
About $5.0 billion |
Further decline |
The 2022 peak reflected strong GLP-1 demand, limited supply of competing products, continued expansion in Type 2 diabetes treatment, and Trulicity’s established reimbursement position. The subsequent decline coincided with Mounjaro’s rapid uptake and the broadening of semaglutide and tirzepatide use.
Mounjaro is replacing Trulicity within Lilly’s own portfolio. This creates a mixed financial effect for Lilly:
- Trulicity sales decline.
- Mounjaro sales increase at a higher growth rate.
- Lilly retains patients within its diabetes franchise.
- The company shifts revenue toward a product with stronger weight-loss efficacy and broader future indication potential.
Trulicity therefore has strategic value even as its standalone revenue declines. It provides prescriber familiarity, payer access, manufacturing infrastructure, and a patient base that Lilly can target for switching.
What is driving the Trulicity market decline?
Mounjaro and Zepbound substitution
Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. It has generally delivered greater weight loss than dulaglutide in comparative clinical practice and has rapidly gained share among patients seeking improved glycemic control and weight reduction.
Zepbound, also containing tirzepatide, is approved for chronic weight management. That indication gives Lilly a second commercial channel outside traditional diabetes prescribing. Trulicity lacks an equivalent obesity label.
Ozempic and Wegovy competition
Novo Nordisk’s semaglutide franchise remains a direct threat. Ozempic competes in Type 2 diabetes, while Wegovy competes in obesity. Both benefit from strong clinical awareness, high demand, and a large prescriber base.
Trulicity retains advantages in cardiovascular outcomes evidence and long-term use experience, but those advantages have not prevented market-share pressure from newer GLP-1 and dual-incretin therapies.
Supply and access dynamics
GLP-1 demand has repeatedly exceeded supply. Shortages affected Mounjaro, Ozempic, Wegovy, and Trulicity at different points. As manufacturing capacity expands, prescribing decisions are increasingly driven by efficacy, weight loss, payer coverage, dose availability, and patient persistence rather than supply alone.
Coverage restrictions also affect the market. Employers, Medicare plans, Medicaid programs, and commercial insurers have tightened utilization management for obesity medicines because of their high budget impact. Diabetes coverage is generally more established, which supports Trulicity’s residual demand.
Pricing and gross-to-net pressure
Trulicity is a mature branded biologic. Lilly faces increasing pressure from rebates, formulary competition, and payer negotiations. A declining product may require higher discounts to retain preferred placement, reducing net price even before biosimilar competition emerges.
When does Trulicity lose exclusivity?
The core U.S. exclusivity period for Trulicity has expired. The product’s five-year new chemical entity exclusivity ended several years after its 2014 approval. The relevant remaining protection is patent-based rather than regulatory exclusivity-based.
The main U.S. composition and use patent estate is generally associated with expiration around 2027, subject to patent-specific terms, terminal disclaimers, patent-term adjustment, pediatric exclusivity, and any litigation outcome.[5]
| Exclusivity category |
Trulicity position |
| FDA approval |
2014 |
| Five-year NCE exclusivity |
Expired |
| Six-month pediatric exclusivity |
No material remaining exclusivity identified in current commercial planning |
| Core U.S. patent risk window |
Approximately 2027 |
| Biosimilar competition before core patent expiry |
Possible only if patent and regulatory barriers are overcome |
| Generic competition |
Conventional ANDA route is not the principal pathway for this biologic |
The 2027 date should be treated as the core market-entry reference point, not as a guaranteed launch date. Patent litigation, regulatory review, manufacturing readiness, and settlement terms can move effective competition later.
What patents protect Trulicity?
Trulicity’s protection is based on a portfolio covering dulaglutide, GLP-1 fusion-protein structures, therapeutic use, formulations, and delivery systems. The commercially significant categories are:
- The dulaglutide molecule and related protein architecture.
- Use of dulaglutide for glycemic control in Type 2 diabetes.
- Dose-escalation and administration regimens.
- Pharmaceutical compositions and liquid formulations.
- Single-dose pen and injection-device configurations.
- Manufacturing and purification methods.
The strongest practical barrier is usually the composition-of-matter or core molecule patent. Formulation and device patents can delay or complicate competition, but they may not prevent every biosimilar or follow-on product from entering if the competing product uses a different device or formulation.
Eli Lilly is the principal owner and commercial sponsor of Trulicity. No major third-party licensing transaction is central to Trulicity’s current commercial economics. The product was developed within Lilly’s incretin research and development platform.
Is Trulicity subject to Paragraph IV challenges?
Paragraph IV litigation is principally a Hatch-Waxman mechanism for small-molecule drugs submitted through an abbreviated new drug application. Trulicity is a biologic approved under a BLA, so a conventional ANDA and Paragraph IV pathway are not the standard route for competition.
A follow-on dulaglutide product would generally be expected to use the FDA’s biosimilar framework under Section 351(k) of the Public Health Service Act. The relevant patent process is the statutory “patent dance,” not a conventional Paragraph IV certification.
This distinction matters for launch timing:
- A small-molecule generic can rely on an ANDA and challenge Orange Book patents.
- A dulaglutide biosimilar must establish biosimilarity to the reference product.
- The biosimilar applicant must manage BLA-related patent disclosures and litigation.
- Interchangeability requires a separate showing under FDA standards.
- Manufacturing comparability is more demanding than for a conventional generic.
Public market analysis should therefore distinguish between an actual FDA biosimilar application, a patent challenge, and an ordinary generic filing. They do not carry the same legal or commercial significance.
What is the Orange Book status of Trulicity?
Trulicity is listed in FDA biologics and drug-reference systems, but the product’s competitive framework is not identical to that of an oral small-molecule drug. The Orange Book remains relevant to listed patents and reference-product information, while the Purple Book and the BLA framework are more relevant to biosimilar competition.[6]
The key commercial question is whether Lilly has enforceable patent claims that cover a biosimilar’s active molecule, dosing regimen, formulation, or delivery device. A biosimilar applicant may attempt to avoid selected device or formulation claims while pursuing a product that remains sufficiently similar to the reference biologic.
How strong is the Trulicity patent estate?
Trulicity’s patent estate is commercially meaningful but aging.
Strengths
- Core protection covers a differentiated recombinant fusion protein.
- The product has a large clinical and commercial record.
- Manufacturing know-how creates additional entry barriers.
- Device and formulation patents can increase development and litigation costs.
- Lilly has substantial financial resources to defend the franchise.
Weaknesses
- The core patent window approaches 2027.
- Regulatory exclusivity has expired.
- The product has no obesity indication.
- Competing products have stronger weight-loss positioning.
- A biosimilar does not need to reproduce every commercial feature of the reference product.
- Revenue erosion may reduce Lilly’s incentive to defend marginal secondary patents aggressively.
The estate is stronger against an immediate full substitution than against eventual multi-product biosimilar entry. The likely outcome is a staged erosion process involving patent settlements, limited launches, and payer-driven switching rather than an overnight collapse.
What generic or biosimilar launch risks exist?
The principal launch scenarios are:
Scenario 1: Delayed competition after patent expiry
A biosimilar sponsor waits for the core patent expiry and launches after resolving secondary patents. This is the lowest-litigation scenario and could produce rapid price pressure if multiple manufacturers enter.
Scenario 2: At-risk launch
A biosimilar sponsor launches before all asserted patents expire after challenging their validity or scope. Lilly could seek an injunction and damages. This scenario creates substantial legal exposure for the entrant but may accelerate market disruption.
Scenario 3: Settlement with a licensed entry date
Lilly and one or more biosimilar manufacturers agree to an entry date before or near the expiration of the last meaningful patent. A settlement could preserve price while granting Lilly control over the timing of erosion.
Scenario 4: Slow biosimilar adoption
Even after legal entry, uptake remains limited because physicians and payers favor established GLP-1 products, the biosimilar lacks interchangeability, or Lilly offers contracting concessions. This would produce gradual rather than immediate erosion.
Manufacturing is a material barrier. Dulaglutide is a complex recombinant protein requiring cell-line development, purification, analytical characterization, stability testing, sterile fill-finish, and a reliable pen or injection presentation. These requirements limit the number of credible entrants.
What is the biosimilar risk for Trulicity?
No biosimilar has displaced Trulicity in the U.S. market through the latest publicly available period covered here. The long-term risk is real but less immediate than the competitive risk from Mounjaro, Ozempic, Wegovy, and other branded incretin products.
The first entrant would need to demonstrate high analytical and functional similarity, satisfy FDA clinical and immunogenicity requirements, secure manufacturing capacity, and resolve Lilly’s patent claims. The commercial opportunity must justify those costs while the market is already moving toward newer agents.
For that reason, branded GLP-1 competition is currently more important to Trulicity revenue than biosimilar competition. Biosimilar entry becomes more significant after the core patent expiry and if Trulicity retains a large price-sensitive patient population.
What litigation and settlement issues affect Trulicity?
The principal litigation issues are expected to involve:
- Validity of core dulaglutide patents.
- Infringement by follow-on biologics.
- Patent-term adjustment and terminal disclaimers.
- Formulation and device claims.
- Biosimilar disclosure and patent-dance compliance.
- Injunctive relief against pre-expiry launch.
- Damages and settlement-based entry dates.
Publicly disclosed information does not establish a broad, final settlement framework that determines the entire U.S. Trulicity market. Individual patent disputes or confidential agreements may affect particular entrants without changing the overall franchise timeline.
How does Trulicity compare with Mounjaro and Ozempic?
| Product |
Active ingredient |
Mechanism |
Main commercial advantage |
Main Trulicity threat |
| Trulicity |
Dulaglutide |
GLP-1 agonist |
Established weekly diabetes product |
Mature product and lower growth |
| Mounjaro |
Tirzepatide |
GIP/GLP-1 agonist |
Strong glycemic and weight-loss efficacy |
Lilly-to-Lilly substitution |
| Ozempic |
Semaglutide |
GLP-1 agonist |
Strong demand and brand recognition |
Direct diabetes competition |
| Wegovy |
Semaglutide |
GLP-1 agonist |
Obesity indication |
Captures weight-management patients |
| Zepbound |
Tirzepatide |
GIP/GLP-1 agonist |
Obesity indication and high efficacy |
Expands Lilly’s own replacement channel |
| Rybelsus |
Oral semaglutide |
GLP-1 agonist |
Oral administration |
Avoids injection for selected patients |
Trulicity’s best defense is its clinical familiarity, established coverage, weekly dosing, and cardiovascular outcomes evidence. Its weakest point is the lack of a weight-management indication and lower perceived efficacy relative to tirzepatide and high-dose semaglutide.
What is Trulicity’s future revenue trajectory?
The base case is continued annual decline as Mounjaro and Zepbound absorb Lilly’s growth investment and competing GLP-1 products expand. Revenue may remain in the multibillion-dollar range for several years because of Trulicity’s scale, but the product is unlikely to return to its 2022 peak without a major change in positioning.
Revenue exposure is material but manageable for Lilly:
- Trulicity remains one of Lilly’s largest products.
- Its decline is offset by Mounjaro and Zepbound growth.
- Margin pressure may increase as rebates rise.
- Patent expiry could produce a second decline phase.
- Lilly’s total corporate growth is increasingly tied to newer incretin and oncology products.
The critical financial variable is not whether Trulicity declines. It is whether Lilly can convert Trulicity patients into higher-value tirzepatide users before biosimilar competition reduces the franchise’s remaining cash flow.
Key Takeaways
- Trulicity sales peaked at approximately $7.4 billion in 2022 and have since declined.
- Mounjaro, Zepbound, Ozempic, and Wegovy are the principal commercial threats.
- Trulicity’s five-year regulatory exclusivity has expired.
- Core U.S. patent protection is generally expected to become a major entry issue around 2027.
- Conventional Paragraph IV litigation is not the primary competitive pathway because Trulicity is a biologic.
- Biosimilar entry requires a 351(k) application and presents higher manufacturing and regulatory barriers than a conventional generic.
- The product’s lack of an obesity indication weakens its long-term growth prospects.
- Lilly can offset much of the revenue decline through internal switching to Mounjaro and Zepbound.
- The most likely erosion pattern is gradual, driven first by branded substitution and later by biosimilar competition.
FAQs
Can Trulicity be substituted automatically with Mounjaro?
No. Trulicity and Mounjaro contain different active ingredients, and automatic substitution depends on the applicable prescription, payer, state, and pharmacy rules.
Does Trulicity have an obesity indication?
No. Trulicity is approved for Type 2 diabetes and cardiovascular-risk reduction in the relevant diabetic population, not chronic weight management.
Is dulaglutide difficult to manufacture?
Yes. Dulaglutide is a recombinant fusion protein requiring specialized biologic manufacturing, analytical testing, purification, sterile processing, and delivery-device production.
Will a Trulicity biosimilar be interchangeable immediately after approval?
Not necessarily. FDA interchangeability requires additional regulatory requirements beyond basic biosimilarity, and a biosimilar may launch without interchangeable status.
Does Lilly have a licensing partner for Trulicity?
No major licensing partner is central to Trulicity’s disclosed commercial structure. Lilly is the principal developer, owner, and marketer.
References
- Eli Lilly and Company. (2024). Annual report 2023.
- Eli Lilly and Company. (2025). Annual report 2024.
- U.S. Food and Drug Administration. (2014). FDA approves Trulicity to treat type 2 diabetes.
- Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., et al. (2019). Dulaglutide and cardiovascular outcomes in type 2 diabetes. The Lancet, 394(10193), 121-130.
- U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent-status records for dulaglutide-related patents.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations and Purple Book: Database of licensed biological products.
